Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
 
Home
 
Registration
Keynote Speakers (TBA)
Industry Panel Discussion (TBA)

 

Invest, Partner and Network with the Most Promising Early- to Late-Stage Medical Technology Companies and the Biggest Deal Makers in the Medtech Business Development and Investment Communities from Both Sides of the Atlantic

For more information, please contact Kristy Grimes at 480-985-9512, 888-202-5939 toll-free in the U.S., or e-mail in3@windhover.com

In3 Europe - Paris is Medtech Insight and Windhover Information’s 30th In3 event – find out for yourself why these first-rate events are considered the most important venue of their kind for key investors from around the world interested in the medical device space.

Program Benefits:

  • Hear presentations from 30+ promising early- to late-stage device companies from around the globe, each followed by one-on-one meetings in private breakout rooms
  • Network with 150+ key deal makers in the device and investment communities from both sides of the Atlantic
  • Gain valuable, actionable insight with plenary sessions by device industry thought leaders sharing their in-the-trenches experiences in building, funding and selling their companies
  • Learn from timely, informative and interactive panel discussions/case studies covering a variety of topics impacting medical device innovation and investment in the U.S., Europe, and other regions
  • Table-top exhibits and product prototypes by presenting companies during a networking reception
  • Workshops for start-up companies

… and much, much more!

Presentations from our hand-selected group of cutting-edge early- to late-stage companies will encompass a wide variety of high-growth device sectors, including:

  • Cardiovascular Therapeutics and Diagnostics
  • Diagnostics
  • Drug Delivery
  • Imaging and Image-Guided Surgery
  • Minimally Invasive Surgery
  • Nanotechnology
  • Neurostimulation
  • Oncology
  • Orthopedics and Spine
  • Peripheral Vascular
  • Stem Cells
  • Stroke Management
  • Tissue Engineering
  • Wound Management

... to mention only a few.
Advisory Board

Jeffrey Barnes
General Partner
Oxford Bioscience Partners

Annette Campbell-White
Senior Managing Member MedVenture Associates

Michael Carusi
General Partner
Advanced Technology Ventures

Luke Evnin
General Partner
MPM Capital

Richard M. Ferrari
Managing Director
DeNovo Ventures

William T. Harrington
Partner
Three Arch Partners

Ross A. Jaffe
Managing Director
Versant Ventures

Ellen Koskinas
Partner
InterWest Partners

Josh Makower
Venture Partner
NEA

John Maroney
General Partner
Delphi Ventures

David Milne
Managing Partner
SV Life Science Advisers

Trevor J. Moody
Partner
Frazier Healthcare Ventures

Jesse I Treu
Partner
Domain Associates
back to top

Presenting Companies

Presenting Companies
Locations		 Technologies
Arterial Remodeling Technologies (ART)
Paris, France 		ART has developed Biodegradable peripheral and coronary polymer stents that promote the natural remodelling of the injured artery after angioplasty.
Axess Vision Technology (First-Time Presenter)
Lyon, France 		AVT develops single use, sterile, flexible video-endoscopes which may be used at the patient bedside and which avoid all cross-contamination risks.
BiancaMed Limited (First-Time Presenter)
Dublin, Ireland 		(technology description coming soon)
Biomedix S.A
Geneva, Switzerland 		Endoscopie treatment of GERD, obesity and Irritable Bowel Syndrome (IBS).
Biospace
Paris, France 		Biospace - Ultra low dose, 2D/3D X-ray imaging for orthopedics, rheumatology and general radiology
Cardiatis
Belgium 		FluidSmart 3D Multilayer Technology Platform to Treat Aneurysms by Modulating Hemodynamic Flow
Cardio³ Biosciences SA
Braine L'Alleud, Belgium 		Cardio³ BioSciences is developing an optimal cell transplant solution for curing cardiovascular diseases and, in particular, heart failure. The complete solution is composed of two products: C-Cure™ and C-Cath™. C-Cure™ is the first bio-therapeutic designed from autologous stem cells committed to a cardiac lineage before implantation. C-Cath™ is a catheter that allows for the accurate transmyocardial injection of C-Cure™.
Cardiola, Ltd. (First-Time Presenter)
Winterthur, Switzerland 		Non-invasive Chronic Heart Failure treatment device with CE certification using patented Muscular Counter Pulsation (MCP) technology.
Ceragenix Pharmaceuticals
Denver, CO 		Ceragenix Pharmaceuticals is developing its "Cerashield" line of antimicrobial coatings to prevent microbial colonization and biofilm formation of endotracheal tubes and other indwelling medical devices.
Ceramconcept LLC
Paris, France 		Total hip replacement system that combines ceramic (resistance to wear) and double mobility (resistance to dislocation).
ES Vascular Ltd. (First-Time Presenter)
Haifa, Israel 		First ever endovascular staplers approved in the EU for AAA; under further development for cardio, minimally-invasive and peripheral vascular indications
Gendel Ltd (First-Time Presenter)
Coleraine, United Kingdom 		Gendel has developed CEFUS therapy (Combined Electric Field and UltraSound), a novel breakthrough in the treatment of solid tumours without the need for chemotherapy.
InitiaRT
Petach Tikva, Israel 		InitiaRT Image Guided Radiation Therapy portfolio includes beam steering, target tracking and treatment planning solutions to the external beam radiation therapy market.
JenaValve Technology GmbH
München, Germany 		JenaValve Technology is a medical device company specialized in developing minimally-invasive heart valve replacement systems.
MagForce Nanotechnologies AG
Berlin, Germany 		MagForce develops a cancer treatment using magnetic nanoparticles that are heated in an alternating magnetic field.
Mini-Lap, Inc. (First-Time Presenter)
Ashton, NY 		A full line of precision crafted ultra-minimally invasive surgical instruments designed by an MIS surgeon.
MINVASYS
Gennevilliers, France 		A true dedicated coronary bifurcation stent and delivery system with the next generation polymer-free abluminal drug eluting technology.
mNemoscience GmbH
Aachen, Germany 		mNemoscience is pioneering the design and manufacture of innovative biocompatible shape memory polymers (BIO-SMP) which can be programmed to change shapes and rigidity when an initiating stimulus, such as e.g. change in temperature, is applied. Further programmable key features are varying rates of biodegradation and outstanding mechanical properties which overcome the material limitations of other materials.
Nanobiotix (First-Time Presenter)
Labege Cedex, France 		New treatments for cancer based on the combined application of nanotechnologies and biotechnologies
NanoPowers SA (First-Time Presenter)
Lausanne, Switzerland 		NanoPowers SA - Proprietary artificial muscle technology to restore muscle function in humans.
Nerites Corporation
Madison, WI 		Water resistant adhesives derived from mussels used as tissue adhesives and anti-bacterial coatings.
OTR3 (FIrst-Time Presenter)
Paris, France 		Pending CE marked Sugar based Matrix Regenerative medicine device treats skin ulcers and reduces amputation
Ovalum Ltd. (First-Time Presenter)
Rehovot, Israel 		Ovalum Ltd. - Minimally invasive product for opening completely blocked coronary and peripheral arteries.
Photo Dynamic Therapy
Vienna, Austria 		"Plug&play"-system to treat non-invasively curative and palliative tumors and precursors specific to patients' individual need.
Praxim, SA
La Tronche, France 		Praxim develops innovative computer integrated robotic instrumentation and navigation tools for orthopedic surgery
PreMD Inc. (First-Time Presenter)
Toronto, Canada 		PreMD develops non-invasive tests for the risk assessment of cardiovascular disease and the detection of early-stage colorectal, lung and breast cancer.
ProRhythm, Inc.
Ronkonkoma, NY 		ProRhythm's technology uses high-intensity focused ultrasound in a catheter to treat atrial fibrilation.
Retina Implant AG (First-Time Presenter)
Reutlingen, Germany 		Retina Implant plans to deliver the first implanted electronic subretinal device, to give back to visually blinds parts of lost sight.
Science & Technology International
Honolulu, HI 		Development and commercialization of Virtual BiopsyR imaging systems software for minimally invasive cancer detection.
Symetis SA (First-Time Presenter)
Lausanne, Switzerland 		2nd generation trans-apical aortic valve replacement system. In-vivo validation on-going. First-in-man Q3/09
SyntheMed, Inc.
Iselin, NJ 		SyntheMed’s focus is the development of products, based on their proprietary, bioresorbable polymer technology, that reduce post-operative surgical adhesions.
Vivolution A/S (First-Time Presenter)
Alleroed, Denmark 		Vivolution manufactures and sells a surgical sealant and a gel to treat chronic wounds. Both are based on the individual patients own blood. A third product can be used as a drug delivery media for topical use.
Vivoxid
Turku, Finland 		Vivoxid is a global developer of medical nanotech surfaces & biocompatible resorbable biomaterials.
Xylos Corporation
Langhorne, PA 		Biocellulose technology for the treatment, repair, and replacement of human tissue that eliminates the risks, complications and limitations inherent in animal, human and synthetic biomaterials
 

Benefits of Attending:

  • Potential acquirers/funding partners will able to meet and screen over 30 first-rate investment possibilities in just 1.5 well-orchestrated days, via focused presentations covering their widely varied technologies, stage of development and testing, potential markets, management teams, regulatory timeline, patent protection, competitive strategy, funding needed, among many other key details, and private break-out sessions, among many other networking opportunities.
  • It’s a fact that medical device start-ups face intense competition for a finite amount of available capital funding: In3 Europe - Paris is an ideal setting for emerging company management teams to meet and impress potential investors, from many of the heavy-hitting, top-tier device companies and discerning healthcare investment firms from around the world.
  • All attendees will gain a keen understanding in a short timeframe of the emerging medical technologies on course to make a distinct impact on the intensely competitive and evidence-driven worldwide device industry in the next few years. Register to attend today and get ready to tap into the many opportunities about to emerge in the medtech space!

We have a long and strong track record: Over 1350 emerging medical technology company presenters and over 7200 attendees have participated at In3 events over the past 7 years. We are very proud that many young companies have worked their way up the funding ladder and into the marketplace via the relationships they formed at In3 events. Click here for success stories and testimonials from our past presenters and attendees.

Attendees will include:

  • Presidents
  • CEOs
  • Chairmen
  • Venture Partners
  • Managing Directors
  • Vice Presidents/Directors of Business Development, Marketing, New Technology, Acquisitions, R & D & Sales
  • Senior Investment Analysts/Managers/Directors

…. from these types of companies:

  • Established medical technology companies from around the world seeking technology through licensing, partnering and acquisition to broaden or deepen product lines or build sector strength
  • Venture capitalists and investment bankers, and
  • Medical device, biotech, biopharmaceutical or other company executives seeking investments or partnerships

The med device industry is red hot, with the number of deals now increasing each year, and the European medical device market is changing and evolving rapidly. In3 Europe - Paris is a do-not-miss event for anyone interested in the best-of-the-best emerging medtech companies from around the globe: we are expecting a record number of participants, from both the buy and sell side – hurry and secure your spot today!
back to top

Program Agenda

April 29, 2008
7:30 - 8:30 AM Registration Salon Orsay Foyer
8:30 - 8:35 AM Welcome/Opening Salon Orsay
8:35 - 9:30 AM Panel Discussion: Trends in European Dealmaking and Investing
Several panelists provide unconventional wisdom on the issues faced by today's medical device players, big and small - from identifying hot clinical areas to understanding the changing funding environment to assessing the current state of M&A and IPO's, as well as looking at market adoption trends and evolving device business models in Europe.

David Cassak, Managing Partner, Windhover Information (moderator)

Christophe Douat, Partner, Matignon Investissement & Gestic

Dr. Olivier Litzka, Partner, Edmond de Rothschild Investment Partners

Antoine Papiernik, Managing Partner, Sofinnova Partners

Yuval Binur, Founder & General Partner, Accelerated Technologies Partners

Thom Rasche, Venture Partner, Earlybird Ventures
9:40 - 9:45 AM Moderator - Summit Corporate Services
9:45 - 9:55 AM ProRhythm, Inc.
9:55 - 10:05 AM Nerites Corporation
10:05 - 10:15 AM Vivoxid, Ltd.
10:15 - 10:25 AM Symetis SA
10:25 - 10:35 AM Nano Biotix
10:35 - 10:45 AM NanoPowers SA
10:45 - 10:55 AM SyntheMed, Inc.
10:55 - 11:25 AM Morning Break Salon Orsay Foyer
11:25 - 11:30 AM Moderator - Windhover Information
11:30 - 11:40 AM MagForce Nanotechnologies AG
11:40 - 11:50 AM Cardiola, Ltd.
11:50 - 12:00 PM Xylos Corporation
12:00 - 12:10 PM Arterial Remodeling Technologies
12:10 - 12:20 PM Cardiatis
12:20 - 12:30 PM Ceramconcept, LLC
12:30 - 1:30 PM Lunch Pacific Eiffel Restaurant
1:35 - 1:45 PM Science and Technology International
1:45 - 1:55 PM Photo Dynamic Therapy
1:55 - 2:05 PM Retina Implant GmbH
2:05 - 2:15 PM mNemoscience GmbH
2:15 - 2:25 PM ES Vascular Ltd.
2:25 - 2:35 PM Biomedix, SA
2:35 - 2:45 PM Ovalum Ltd.
2:45 - 2:55 PM Mini-Lap, Inc.
2:55 - 3:05 PM Ceragenix Pharmaceuticals
3:05 - 3:15 PM Cardio³ Biosciences SA
3:15 - 3:45 PM Afternoon Break
3:50 - 3:55 PM Moderator - Windhover Information
3:55 - 4:05 PM JenaValve Technology GmbH
4:05 - 4:15 PM PreMed Inc.
4:15 - 4:25 PM BiancaMed Limited
4:25 - 4:35 PM Vivolution A/S
4:35 - 4:45 PM MINVASYS
4:45 - 6:30 PM Presenting Company Exhibition/Networking Reception Salon Orsay Foyer
April 30, 2008
9:10 - 9:55 AM Registration Salon Orsay Foyer
9:55 - 10:00 AM Welcome/Opening Salon Orsay
10:00 - 11:00 AM State of the Medical Device Industry, David Cassak, Managing Partner, Windhover Information
Key discussion highlights include:
-Hot clinical areas - which therapeutic markets attracted the most attention in 2007, and which ones will stay hot in 2008? What new areas of interest will emerge?
- M&A: Identifying the most important deals and deal trends from 2007 and what that means for M&A in the year ahead.
- IPOs: The public market remained open for medtech companies in 2007 - who were the winners and losers, and will the window remain open in 2008?
- Regulatory/legal: A look at important regulatory, reimbursement and legal issues that will play increasingly important roles in device companies' strategies.
- What are some key growth trends for start-ups?
- Where is the funding going?
- How are device stocks performing?
- What are the new financing models?
- How are large companies sustaining growth?
- How are companies structuring and valuing deals?
11:05 - 11:10 AM Moderator - Summit Corporate Services
11:10 - 11:20 AM Praxim, SA
11:20 - 11:30 AM Gendel Ltd.
11:30 - 11:40 AM InitiaRT
11:40 - 11:50 AM Biospace
11:50 - 12:00 PM Axess Vision Technology
12:00 - 12:10 PM OTR3
12:10 - 1:10 PM Lunch Pacific Eiffel Restaurant
1:10 - 1:10 PM Conference Concludes

 

*Cancellation Policy: Cancellation Policy: The last day to cancel your registration for a refund, minus a $300 processing fee, is March 30, 2008. After that, you may send another delegate from your company.


Sponsored by:

Major Supporting Publication